Lisa Schütz1, Donald Lobsien2, Dominik Fritzsch2, Solveig Tiepolt1, Peter Werner1, Matthias L Schroeter3,4, Jörg Berrouschot5, Dorothee Saur6, Swen Hesse1,4, Thies Jochimsen1, Michael Rullmann1, Bernhard Sattler1, Marianne Patt1, Hermann-Josef Gertz7, Arno Villringer3,4, Joseph Claßen6, Karl-Titus Hoffmann2, Osama Sabri1,4, Henryk Barthel8. 1. Department of Nuclear Medicine, Leipzig University Hospital, Liebigstr. 18, 04103, Leipzig, Germany. 2. Department of Neuroradiology, Leipzig University Hospital, 04103, Leipzig, Germany. 3. Day Clinic for Cognitive Neurology, Leipzig University Hospital & Max Planck Institute for Human Cognitive and Brain Sciences, 04103, Leipzig, Germany. 4. IFB Adiposity Diseases, Leipzig University Hospital, 04103, Leipzig, Germany. 5. Clinical Centre Altenburger Land, 04600, Altenburg, Germany. 6. Department of Neurology, Leipzig University Hospital, 04103, Leipzig, Germany. 7. Department of Psychiatry, Leipzig University Hospital, 04103, Leipzig, Germany. 8. Department of Nuclear Medicine, Leipzig University Hospital, Liebigstr. 18, 04103, Leipzig, Germany. barh@medizin.uni-leipzig.de.
Abstract
PURPOSE: Established Alzheimer's disease (AD) biomarker concepts classify into amyloid pathology and neuronal injury biomarkers, while recent alternative concepts classify into diagnostic and progression AD biomarkers. However, combined amyloid positron emission tomography/magnetic resonance imaging (PET/MRI) offers the chance to obtain both biomarker category read-outs within one imaging session, with increased patient as well as referrer convenience. The aim of this pilot study was to investigate this matter for the first time. METHODS: 100 subjects (age 70 ± 10 yrs, 46 female), n = 51 with clinically defined mild cognitive impairment (MCI), n = 44 with possible/probable AD dementia, and n = 5 with frontotemporal lobe degeneration, underwent simultaneous [18F]florbetaben or [11C]PIB PET/MRI (3 Tesla Siemens mMR). Brain amyloid load, mesial temporal lobe atrophy (MTLA) by means of the Scheltens scale, and other morphological brain pathologies were scored by respective experts. The patients/caregivers as well as the referrers were asked to assess on a five-point scale the convenience related to the one-stop-shop PET and MRI approach. RESULTS: In three subjects, MRI revealed temporal lobe abnormalities other than MTLA. According to the National Institute on Aging-Alzheimer's Association classification, the combined amyloid-beta PET/MRI evaluation resulted in 31 %, 45 %, and 24 % of the MCI subjects being categorized as "MCI-unlikely due to AD", "MCI due to AD-intermediate likelihood", and "MCI due to AD-high likelihood", respectively. 50 % of the probable AD dementia patients were categorized as "High level of evidence of AD pathophysiological process", and 56 % of the possible AD dementia patients as "Possible AD dementia - with evidence of AD pathophysiological process". With regard to the International Working Group 2 classification, 36 subjects had both positive diagnostic and progression biomarkers. The patient/caregiver survey revealed a gain of convenience in 88 % of responders as compared to a theoretically separate PET and MR imaging. In the referrer survey, an influence of the combined amyloid-beta PET/MRI on the final diagnosis was reported by 82 % of responders, with a referrer acceptance score of 3.7 ± 1.0 on a 5-point scale. CONCLUSION: Simultaneous amyloid PET/MRI is feasible and provides imaging biomarkers of all categories which are able to supplement the clinical diagnosis of MCI due to AD and that of AD dementia. Further, patient and referrer convenience is improved by this one-stop-shop imaging approach.
PURPOSE: Established Alzheimer's disease (AD) biomarker concepts classify into amyloid pathology and neuronal injury biomarkers, while recent alternative concepts classify into diagnostic and progression AD biomarkers. However, combined amyloid positron emission tomography/magnetic resonance imaging (PET/MRI) offers the chance to obtain both biomarker category read-outs within one imaging session, with increased patient as well as referrer convenience. The aim of this pilot study was to investigate this matter for the first time. METHODS: 100 subjects (age 70 ± 10 yrs, 46 female), n = 51 with clinically defined mild cognitive impairment (MCI), n = 44 with possible/probable AD dementia, and n = 5 with frontotemporal lobe degeneration, underwent simultaneous [18F]florbetaben or [11C]PIB PET/MRI (3 Tesla Siemens mMR). Brain amyloid load, mesial temporal lobe atrophy (MTLA) by means of the Scheltens scale, and other morphological brain pathologies were scored by respective experts. The patients/caregivers as well as the referrers were asked to assess on a five-point scale the convenience related to the one-stop-shop PET and MRI approach. RESULTS: In three subjects, MRI revealed temporal lobe abnormalities other than MTLA. According to the National Institute on Aging-Alzheimer's Association classification, the combined amyloid-beta PET/MRI evaluation resulted in 31 %, 45 %, and 24 % of the MCI subjects being categorized as "MCI-unlikely due to AD", "MCI due to AD-intermediate likelihood", and "MCI due to AD-high likelihood", respectively. 50 % of the probable AD dementiapatients were categorized as "High level of evidence of AD pathophysiological process", and 56 % of the possible AD dementiapatients as "Possible AD dementia - with evidence of AD pathophysiological process". With regard to the International Working Group 2 classification, 36 subjects had both positive diagnostic and progression biomarkers. The patient/caregiver survey revealed a gain of convenience in 88 % of responders as compared to a theoretically separate PET and MR imaging. In the referrer survey, an influence of the combined amyloid-beta PET/MRI on the final diagnosis was reported by 82 % of responders, with a referrer acceptance score of 3.7 ± 1.0 on a 5-point scale. CONCLUSION: Simultaneous amyloid PET/MRI is feasible and provides imaging biomarkers of all categories which are able to supplement the clinical diagnosis of MCI due to AD and that of AD dementia. Further, patient and referrer convenience is improved by this one-stop-shop imaging approach.
Authors: Stefan Teipel; Alexander Drzezga; Michel J Grothe; Henryk Barthel; Gaël Chételat; Norbert Schuff; Pawel Skudlarski; Enrica Cavedo; Giovanni B Frisoni; Wolfgang Hoffmann; Jochen René Thyrian; Chris Fox; Satoshi Minoshima; Osama Sabri; Andreas Fellgiebel Journal: Lancet Neurol Date: 2015-08-26 Impact factor: 44.182
Authors: Niki S M Schoonenboom; Wiesje M van der Flier; Marinus A Blankenstein; Femke H Bouwman; Gerard J Van Kamp; Frederik Barkhof; Philip Scheltens Journal: Neurobiol Aging Date: 2007-01-17 Impact factor: 4.673
Authors: Victor L Villemagne; Rachel S Mulligan; Svetlana Pejoska; Kevin Ong; Gareth Jones; Graeme O'Keefe; J Gordon Chan; Kenneth Young; Henri Tochon-Danguy; Colin L Masters; Christopher C Rowe Journal: Eur J Nucl Med Mol Imaging Date: 2012-03-08 Impact factor: 9.236
Authors: Val J Lowe; Patrick J Peller; Stephen D Weigand; Catalina Montoya Quintero; Nirubol Tosakulwong; Prashanthi Vemuri; Matthew L Senjem; Lennon Jordan; Clifford R Jack; David Knopman; Ronald C Petersen Journal: Neurology Date: 2013-05-03 Impact factor: 9.910
Authors: Yi Su; Brian B Rubin; Jonathan McConathy; Richard Laforest; Jing Qi; Akash Sharma; Agus Priatna; Tammie L S Benzinger Journal: J Nucl Med Date: 2016-01-28 Impact factor: 10.057
Authors: Najmeh Khalili-Mahani; Serge A R B Rombouts; Matthias J P van Osch; Eugene P Duff; Felix Carbonell; Lisa D Nickerson; Lino Becerra; Albert Dahan; Alan C Evans; Jean-Paul Soucy; Richard Wise; Alex P Zijdenbos; Joop M van Gerven Journal: Hum Brain Mapp Date: 2017-02-01 Impact factor: 5.038
Authors: Neetu Soni; Manish Ora; Girish Bathla; Chandana Nagaraj; Laura L Boles Ponto; Michael M Graham; Jitender Saini; Yusuf Menda Journal: Neuroradiol J Date: 2021-03-05